...Good morning and welcome once again to TD Cowen's 6th Annual Oncology Innovation Summit, Insights for ASCO and EHA. I am Phil Nadeau, one of Cowen's biotech analysts, and it's my pleasure to moderate a fireside chat with Syndax Pharmaceuticals. We have with us today CEO Michael Metzger and the Head of R&D Nick Botwood. These are exciting times for Syndax with abstracts at EHA, as well as a launch going on, so I'm sure you're all aware for Revuforj in AML. With that, Michael, I thought I'd kick it to you for an introduction. Can you give us a brief state of the company overview, biggest strengths, biggest challenges, and what do you think Syndax needs to achieve to drive up performance over the next year or two? Michael Metzger ...